Acute effect of zoledronic acid on the risk of cardiac dysrhythmias

The association between serious upper gastrointestinal bleeding and incident bisphosphonate use: a population-based nested cohort study

(2013) Jennifer A Knopp-Sihota et al.   BMC Geriatrics

Bisphosphonate Therapy for Osteoporosis: Benefits, Risks, and Drug Holiday

(2012) Michael McClung et al.   AMERICAN JOURNAL OF MEDICINE

Acute phase response following intravenous zoledronate in postmenopausal women with low bone mass

(2012) Athanasios D. Anastasilakis et al.   BONE

Bisphosphonate use is associated with reduced risk of myocardial infarction in patients with rheumatoid arthritis

(2012) Frederick Wolfe et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Benefits and Risks of Bisphosphonate Therapy for Osteoporosis

(2012) Sundeep Khosla et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Intravenous bisphosphonate therapy and atrial fibrillation/flutter risk in cancer patients: a nationwide cohort study

(2011) R Erichsen et al.   BRITISH JOURNAL OF CANCER

Predictors of incident atrial fibrillation and influence of medications: a retrospective case–control study

(2011) James A Hodgkinson et al.   BRITISH JOURNAL OF GENERAL PRACTICE

Safety of Long-Term Bisphosphonate Therapy for the Management of Osteoporosis

(2011) E. Michael Lewiecki   DRUGS

Bone mineral density, quantitative ultrasound parameters and bone metabolism in postmenopausal women with depression

(2011) Marco Atteritano et al.   Internal and Emergency Medicine

Atrial fibrillation and bisphosphonate therapy

(2011) Michael Pazianas et al.   JOURNAL OF BONE AND MINERAL RESEARCH

The effect of 3 versus 6 years of Zoledronic acid treatment of osteoporosis: A randomized extension to the HORIZON-Pivotal Fracture Trial (PFT)

(2011) Dennis M Black et al.   JOURNAL OF BONE AND MINERAL RESEARCH

2011 ACCF/AHA/HRS Focused Updates Incorporated Into the ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation

(2011) Valentin Fuster et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Impact of Bisphosphonates on the Risk of Atrial Fibrillation

(2010) Patricia A. Howard et al.   American Journal of Cardiovascular Drugs

Characterization of and Risk Factors for the Acute-Phase Response after Zoledronic Acid

(2010) I. R. Reid et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Long-Term Use of Bisphosphonates in Osteoporosis

(2010) Nelson B. Watts et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

RELATIONSHIP OF BASAL HEART RATE VARIABILITY TO IN VIVO CYTOKINE RESPONSES after endotoxin exposure

(2010) Badar U. Jan et al.   SHOCK

Relation of Bisphosphonate Therapies and Risk of Developing Atrial Fibrillation

(2009) T. Jared Bunch et al.   AMERICAN JOURNAL OF CARDIOLOGY

Efficacy of Bisphosphonates in Reducing Fracture Risk in Postmenopausal Osteoporosis

(2009) John P. Bilezikian   AMERICAN JOURNAL OF MEDICINE

Serum 25-hydroxyvitamin D levels modulate the acute-phase response associated with the first nitrogen-containing bisphosphonate infusion

(2009) Francesco Bertoldo et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Atrial fibrillation in fracture patients treated with oral bisphosphonates

(2009) B. Abrahamsen et al.   JOURNAL OF INTERNAL MEDICINE

Oral Bisphosphonates and Risk of Atrial Fibrillation and Flutter in Women: A Self-Controlled Case-Series Safety Analysis

(2009) Anthony Grosso et al.   PLoS One

Use of Alendronate and Risk of Incident Atrial Fibrillation in Women

(2008) Susan R. Heckbert et al.   ARCHIVES OF INTERNAL MEDICINE

Vitamin D status and response to treatment in post-menopausal osteoporosis

(2008) S. Adami et al.   OSTEOPOROSIS INTERNATIONAL